Early Access — free while we kick the tires
EdgarHawk

Mandel-Brehm Josh

Chief Executive Officer

Director Officer
1 filing analyzed · 1 company · Latest 2025-09-11

Companies

Company Buys Sells Direction
Camp4 Therapeutics Corp CAMP 1 0 Net buying

Activity

September 2025
high
Buy
6,060 shares
$9,999
Significance 7/10

Camp4 CEO Josh Mandel-Brehm bought 6,060 shares at $1.65 on 2025-09-11; 6 other insiders also bought within 14 days

Chief Executive Officer Josh Mandel-Brehm purchased 6,060 shares at $1.65 for $10.0K, increasing holdings from 272,357 to 278,417 shares. This open-market buy occurs within a cluster pattern: 6 other insiders also purchased shares within the past 14 days. The stock has recovered 101.4% over the past 30 days and 80.5% over 90 days, though it remains 76.3% below its 52-week high of $11.74. Camp4 is unprofitable (net income of $-12.6M in its latest full fiscal year) despite strong annual revenue growth of 86.3%, with latest quarterly revenue at $1.5M. The coincident buying by multiple insiders at a depressed valuation relative to 52-week highs, coupled with the company's explosive revenue trajectory, suggests insiders may view the current price as attractive amid a recovery phase.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access